Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways.
ACS medicinal chemistry letters June 12, 2025 DOI: 10.1021/acsmedchemlett.5c00263 via PubMed
Summary
AI-generated from the abstractNew non-hallucinogenic compounds based on substituted tryptamines show promise for treating metabolic and neuropsychiatric disorders by selectively targeting 5-HT2A/2C receptors. Two recent patent applications describe analogs that avoid psychedelic effects while offering optimized receptor selectivity, potential metabolic benefits, and the ability to promote neuroplasticity. These agents represent a novel chemical framework for multimodal treatment strategies in brain disorders and metabolic health.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Drug development Drug discovery Pharmaceutical research Novel compounds Therapeutic innovation |
| Key finding | Substituted tryptamines with selective 5-HT2A/2C activity offer therapeutic promise for metabolic and neuropsychiatric disorders without psychedelic effects. |
Abstract
Substituted tryptamines with selective 5-HT2A/2C activity demonstrate therapeutic promise without psychedelic effects. Two recent patent applications describe nonhallucinogenic analogs for metabolic and neuropsychiatric disorders. These agents exhibit optimized receptor selectivity, metabolic synergy, and neuroplastic potential, offering a novel chemical framework for multimodal treatment strategies.